Workflow
健康元(600380):主业转型过渡,业绩符合预期
JoincareJoincare(SH:600380) EBSCN·2025-08-26 02:14

Investment Rating - The report maintains a "Buy" rating for the company, indicating a favorable outlook for investment returns over the next 6-12 months [6]. Core Views - The company is undergoing a transitional phase in its traditional business due to factors such as centralized procurement, while its innovative transformation is progressing in an orderly manner [4]. - The company reported a revenue of 7.898 billion yuan for the first half of 2025, a year-on-year decrease of 4.08%, but the net profit attributable to shareholders increased by 1.10% to 785 million yuan, aligning with market expectations [1][2]. Summary by Sections Financial Performance - In the first half of 2025, the revenue from the chemical preparation segment was 3.768 billion yuan (down 7.51% year-on-year), while the revenue from chemical raw materials and intermediates was 2.525 billion yuan (down 4.48% year-on-year). The traditional Chinese medicine segment saw a revenue increase of 4.29% to 812 million yuan, and health food revenue surged by 35.24% to 244 million yuan [2]. - The gross margin for the pharmaceutical manufacturing sector was 62.53%, a decrease of 1.09 percentage points year-on-year [2]. Business Development - The company is deepening its layout in the respiratory field, with core products performing well despite short-term pressures from centralized procurement policies. Sales of the core product, Tobramycin inhalation solution, increased by 112% year-on-year [3]. - The company is advancing its innovative transformation with a rich pipeline, including an anti-influenza drug expected to be approved in the second half of 2025 and several complex formulations that have received registration [3]. Profit Forecast and Valuation - The profit forecast for the company is set at 1.32 billion yuan for 2025, with projected earnings per share (EPS) of 0.72 yuan. The price-to-earnings (P/E) ratio is expected to be 18 for 2025, decreasing to 14 by 2027 [4][5]. - The report anticipates a gradual recovery in revenue growth, with a projected increase of 0.90% in 2025, followed by higher growth rates in subsequent years [5].